Key Details
Annual ROE
-34.71%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 11, 2022Recent annual earnings:
Mar 01, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with FMTX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Forma Therapeutics Holdings doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Forma Therapeutics Holdings?
- What is the ticker symbol for Forma Therapeutics Holdings?
- Does Forma Therapeutics Holdings pay dividends?
- What sector is Forma Therapeutics Holdings in?
- What industry is Forma Therapeutics Holdings in?
- What country is Forma Therapeutics Holdings based in?
- When did Forma Therapeutics Holdings go public?
- Is Forma Therapeutics Holdings in the S&P 500?
- Is Forma Therapeutics Holdings in the NASDAQ 100?
- Is Forma Therapeutics Holdings in the Dow Jones?
- When was Forma Therapeutics Holdings's last earnings report?
- When does Forma Therapeutics Holdings report earnings?
What is the primary business of Forma Therapeutics Holdings?
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
What is the ticker symbol for Forma Therapeutics Holdings?
The ticker symbol for Forma Therapeutics Holdings is NASDAQ:FMTX
Does Forma Therapeutics Holdings pay dividends?
No, Forma Therapeutics Holdings does not pay dividends
What sector is Forma Therapeutics Holdings in?
Forma Therapeutics Holdings is in the Healthcare sector
What industry is Forma Therapeutics Holdings in?
Forma Therapeutics Holdings is in the Biotechnology industry
What country is Forma Therapeutics Holdings based in?
Forma Therapeutics Holdings is headquartered in United States
When did Forma Therapeutics Holdings go public?
Forma Therapeutics Holdings's initial public offering (IPO) was on 19 June 2020
Is Forma Therapeutics Holdings in the S&P 500?
No, Forma Therapeutics Holdings is not included in the S&P 500 index
Is Forma Therapeutics Holdings in the NASDAQ 100?
No, Forma Therapeutics Holdings is not included in the NASDAQ 100 index
Is Forma Therapeutics Holdings in the Dow Jones?
No, Forma Therapeutics Holdings is not included in the Dow Jones index
When was Forma Therapeutics Holdings's last earnings report?
Forma Therapeutics Holdings's most recent earnings report was on 11 November 2022
When does Forma Therapeutics Holdings report earnings?
The date for Forma Therapeutics Holdings's next earnings report has not been announced yet